Corbus appoints Nishant Saxena as first Chief Business Officer; schedules CRB-701 data call

Corbus Pharmaceuticals Holdings, Inc.

Nishant Saxena appointed CBO; base salary $470K, 192,300 options and 58,300 RSUs as initial equity.
Conference call on May 26 at 8:00 a.m. EDT to discuss updated Phase 1/2 CRB-701 data (data cut April 1).
Upcoming milestones: initiation of registrational study of CRB-701 in second-line HNSCC and completion of CANYON-1 Phase 1b for CRB-913 (CB1 inverse agonist).
Brent Pfeiffenberger granted 24,700 nonqualified options and 7,500 RSUs as initial board equity awards.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brent Pfeiffenberger

Director

CRBP · Corbus Pharmaceuticals Holdings, Inc.

Filed: May 21, 2026, 8:15 AM ET

On May 19, 2026, the Compensation Committee granted Brent Pfeiffenberger the following initial equity awards under the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) in connection with his appointment to the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Brent Pfeiffenberger was appointed as Director at Corbus Pharmaceuticals Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On May 19, 2026, the Compensation Committee granted Brent Pfeiffenberger the following initial equity awards under the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) in connection with his appointment to the Board

View on SEC.gov

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-233507

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.